CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
belinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00303953
NCT00303953Phase 2Completed
CompareCT.gov

Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)·interventional·Posted Mar 17, 2006·Updated May 12, 2014

In Brief

A Phase 2 clinical trial evaluating belinostat for Recurrent Adult Burkitt Lymphoma and Recurrent Adult Diffuse Large Cell Lymphoma. Completed, enrolled 22 participants across 123 sites.

Detailed Summary

This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 17, 2006
Enrollment StartJan 1, 2006
Primary CompletionJan 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 20.3 years ago

Interventions

belinostatdrug

Given IV